Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IQV, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Esomeprazole Magnesium | Erosive Esophagitis | Phase 3 · NCT05267613 | Completed |
| Medi-546 | Systemic Lupus Erythematosus | Phase 3 · NCT04877691 | Active not recruiting |
| GSK3511294 (Depemokimab) | Asthma | Phase 3 · NCT04718389 | Completed |
| Olorofim | Invasive Aspergillosis | Phase 3 · NCT05101187 | Completed |
| Oregovomab | Carcinoma, Ovarian Epithelial | Phase 3 · NCT04498117 | Active not recruiting |
| Liposomal Amphotericin B | Invasive Aspergillosis | Phase 3 · NCT05101187 | Completed |
| J147 Emulsion for Injection | Acute Ischemic Stroke | Phase 2 · NCT07430917 | Recruiting |
| NOC-110 | Refractory or Unexplained Chronic Cough | Phase 2 · NCT06504446 | Active not recruiting |
| OG-6219 | Endometriosis | Phase 2 · NCT05560646 | Completed |
| Bedaquiline | Drug Susceptible Pulmonary Tuberculosis | Phase 2 · NCT07525427 | Recruiting |
| Efgartigimod | Primary Sjögren's Syndrome | Phase 2 · NCT06203457 | Completed |
| TBD11 (300 mg) | Healthy Adult Participants | Phase 1 · NCT07883226 | Recruiting |
| Anti-CD137 Agonistic Monoclonal Antibody CTX-471 | Locally Advanced Solid Tumor | Phase 1 · NCT03881488 | Terminated |
| Talabostat Mesylate | Cancer of Pancreas | Early Phase 1 · NCT04123574 | Withdrawn |
| Out-of-specification obecabtagene autoleucel | Lymphoblastic Leukemia, Acute, Adult | N/A · NCT06799221 | Available |
| Non-orexin receptor antagonist medications for… | Insomnia | N/A · NCT06498128 | Terminated |
Also used in these trials (approved or third-party drugs, not IQV's own candidates): Pegcetacoplan, Benralizumab, Acellular Tissue Engineered Vessel, Mepolizumab, Nirsevimab, Carboplatin, Paclitaxel, Durvalumab (MEDI4736), Olaparib, Futibatinib, Amivantamab, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IQV holds $2.4B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IQV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 14,433,297 | 8.76% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 12,714,783 | 7.72% | 2026-03-31 |
| Harris Associates L.P. | Institution (13F) | 10,442,270 | 6.34% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 7,516,498 | 4.56% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 7,362,427 | 4.47% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 4,425,490 | 2.69% | 2026-09-30 |
| Boston Partners | Institution (13F) | 4,368,759 | 2.65% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 4,316,639 | 2.62% | 2026-09-30 |
| Artisan Partners Limited Partnership | Institution (13F) | 3,461,373 | 2.10% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 2,943,236 | 1.79% | 2026-09-30 |
| Ari Bousbib Chairman, Chief Executive Officer & Pres · +78,264 options |
Insider | 1,379,243 | 0.84% | 2026-07-29 |
| John G Danhakl Director · +3,423 options |
Insider | 31,887 | 0.02% | 2026-04-23 |
Share count 164,800,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-09 filed 2026-11-12 |
Sherbet Eric |
Option exercise (M) | 8,436 | $131.82 | 29,435 |
| 2026-11-09 filed 2026-11-12 |
Sherbet Eric |
Sale (S) | 4,446 | $278.83 | 24,989 |
| 2026-11-09 filed 2026-11-12 |
Sherbet Eric |
Returned to issuer (D) | 3,990 | $278.74 | 20,999 |
| 2026-11-09 filed 2026-11-12 |
Sherbet Eric |
Option exercise (M) | 8,436 | $131.82 | – |
| 2026-11-05 filed 2026-11-09 |
DANHAKL JOHN G |
Option award (A) | 134 | $264.88 | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IQV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →